Concert Pharma down 31% on AVP-786 efficacy questions

Thinly traded micro cap Concert Pharmaceuticals (CNCE -30.5%) is down on more than triple normal volume, albeit on turnover of only 627K shares, in apparent response to study results (still trying to locate) that showed (possibly by collaboration partner Otsuka) non-deuterated dextromethorphan was more active than Concert’s deuterated molecule AVP-786.

https://seekingalpha.com/news/3502350-concert-pharma-31-percent-avpminus-786-efficacy-questions